×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease
PointClickCare Integration Announced by AccessDx Laboratory
19 Feb 2025
AccessDx Laboratory, a nationwide provider of precision medicine and diagnostics solutions, today
...
Leqembi® has received approval for intravenous maintenance treatment in China
Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg/30 mL Multi-Dose Vials
Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders
CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex
Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34
By
Aspera Biomedicines Inc.
Aspera Biomedicines Inc.
18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio
By
Galvanize Therapeutics, Inc.
Galvanize Therapeutics, Inc.
18 May 2026
Peter Menziuso named EVP and President of BD Interventional
By
BD
BD
18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice
By
Ferring Pharmaceuticals
Ferring Pharmaceuticals
17 May 2026
Biohack skin longevity with Futurecode Booster
By
Dermalogica
Dermalogica
16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.
By
AstraZeneca
AstraZeneca
15 May 2026
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)
By
PharmAbcine
Jul 02
Medra Raises $52 Million in Series A Funding to Build Physical AI Scientists
By
Medra
Dec 11
NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation
By
NS Pharma, Inc.
Nov 27
May
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe to Our Monthly Newsletter
Subscribe to Pharmaceutical Era’s monthly newsletter,
Pharmaceutical Leaders Digest
®, to receive timely updates from across the pharmaceutical industry.
I agree with the
Terms and conditions
×
and the
Privacy policy
×
Please enable the javascript to submit this form
Subscribe
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand
